Bioavailability of LY03004 and Risperdal® Consta®

Condition(s) targeted: Schizophrenia; Schizoaffective Disorder

Intervention: LY03004 (Drug); Risperdal® Consta® (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Luye Pharma Group Ltd.

Official(s) and/or principal investigator(s):
Simon Li, Study Chair, Affiliation: Luye Pharma Group Ltd.

This study is to assess the bioavailability of LY03004 compared to Risperdal Consta as well as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat injections

Official title: A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder

Study design: Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal® Consta®

Secondary outcome:

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

The change of the PANSS score for the Preliminary efficacy of LY03004

Detailed description:

- To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25

mg following multiple intramuscular injections at steady-state;

- To evaluate the safety and tolerability of LY03004 following repeated intramuscular

injections

- To evaluate the preliminary efficacy of LY03004 following repeated intramuscular

injections

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Male or female patients aged 18 to 65 years old 2. Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder based on the Mini-International Neuropsychiatric Interview (MINI) 3. Patients must be clinically stable on antipsychotic medications other than risperidone or paliperidone or clozapine for at least 4 weeks prior to screening, based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS) total score less than or equal 70 at Screening Visit 4. Patients with a Body Mass Index in range of 18. 0 to 35. 0 5. Patients with an Informed Consent Form signed by the patient or legally authorized representative Exclusion Criteria: 1. Patients with a mental disorders other than schizophrenia or schizoaffective disorder, according to the DSM-IV-TR 2. Patients who received oral risperidone or paliperidone or clozapine within 14 days prior to screening, or Risperdal® Consta® within 100 days prior to screening or paliperidone palmitate within 10 months prior to screening 3. Patients with neuroleptic malignant syndrome or physical fatigue associated with dehydration or malnutrition 4. Patients who pose a significant risk of a suicide attempt based on history, investigator's judgment or have answered "yes" to the questions 4 or 5 for current or past 30 days on the screening form of the Columbia Suicide Severity Rating Scale (C-SSRS) 5. Patients with a history of sensitivity to akathisia and other EPS, especially with previous use of risperidone or paliperidone 6. Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater than or equal to 7% 7. Patients with a history of or currently having epilepsy or convulsion disorders 8. Patients who have had electroconvulsive therapy within the past 2 months prior to screening 9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2 weeks prior to screening 10. Patients with a history of allergic reaction to risperidone or to the excipients of LY03004 11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months prior to screening 12. Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis 13. Patients who are currently taking medications with primarily CNS activities such as antidepressants, mood stabilizers or anticonvulsants 14. Patients who have participated in a clinical trial of another investigational drug within 30 days prior to screening 15. Female patients who are pregnant or are breastfeeding or are of childbearing potential without adequate use of contraception 16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality, which in the judgment of the investigator would interfere with the subject's ability to participate in the study

Woodland International, Little Rock, Arkansas 72211, United States

Collaborative Neuroscience Network LLC, Long Beach, California 90806, United States

Neuropsychiatric Research Center of Orange County, Orange, California 92868, United States

Comprehensive Clinical Development, Washington, District of Columbia 20016, United States

Compass Research, Leesburg, Florida 34748, United States

Atlanta Center for Medical Research, Atlanta, Georgia 30308, United States

CBH Health LLC, Rockville, Maryland 20850, United States

CRI LifeTree, Marlton, New Jersey 08053, United States

CRI LifeTree, Philadelphia, Pennsylvania 19139, United States

Community Clinical Research Inc, Austin, Texas 78754, United States

Starting date: September 2014
Last updated: March 3, 2015